Financial Times reporting indicates Merck is in preliminary talks to acquire Revolution Medicines for roughly $28–32 billion, a move that would bolster access to Revolution’s late‑stage RAS‑pathway inhibitors such as daraxonrasib. The discussions are reportedly not finalized and other bidders may be involved. The potential acquisition comes as Merck faces patent expirations on Keytruda and seeks to refresh its oncology pipeline. Media sources caution negotiations remain fluid; however, the reported interest highlights major pharma urgency to add targeted oncology assets via M&A.